

**Human-Relevant Non-Animal Methodologies (NAMs)**  
**Specialised Models Series: Musculoskeletal & Reproductive**  
**Section 7 – Reference 7.1 - 7.5**

**Full Scope Roadmap**

**7.1 Musculoskeletal / Joint & Arthritis Models**

**7.2 Reproductive / Placental / Developmental Models**

**7.3 Dental / Oral Models**

**7.4 Bone / Osteoporosis Models**

**7.5 Cartilage Regeneration Models**

**Version 1.0 | June 2026 Edition**

*Compiled for the Alliance for Cruelty-Free Science by Georgina Rednall*

*Prepared for Academic Leadership, Animal Welfare & Ethical Review Bodies (AWERB), and  
Principal Investigators*

**1. Executive Summary & Legal-Scientific Imperative**

The UK Animals (Scientific Procedures) Act 1986 (ASPA) imposes a statutory duty on the Secretary of State to ensure compliance with the principles of replacement, reduction, and refinement (the 3Rs). The statute dictates that whenever a specialised, scientifically satisfactory replacement strategy not involving protected animals is available, it must be utilised.

Historically, musculoskeletal, reproductive, dental, and bone research has relied heavily on invasive rodent and large animal surgical models, as well as in vivo toxicology assays that fail to capture complex tissue physiology, dynamic mechanical loading, and human-specific developmental pathways. These translational failures occur due to:

**Skeletal and Mechanical Mismatch:** Rodent models fail to replicate human weight-bearing mechanics and bone remodelling rates.

**Placental Barrier Divergence:** The structure and transport kinetics of the rodent placenta differ significantly from the human syncytiotrophoblast, leading to poor developmental toxicity predictions.

**Articular Divergence:** Animal cartilage repair studies often show healing patterns not replicable in humans due to distinct joint load profiles.

To bridge this gap, this roadmap outlines a transition strategy toward human-relevant Non-Animal Methodologies (NAMs), leveraging advanced microphysiological systems (MPS), 3D bioprinting, and Weight of Evidence (WoE) dossiers to support institutional Project License (PPL) applications.

2. System-Specific NAM Frameworks & Focus Areas

| Focus Area                 | Primary Animal Model (Legacy)                         | NAM Replacement Technology                              | Key Applications                                              | Benefits for Universities & 3Rs                     |
|----------------------------|-------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------------|
| 7.1 Musculoskeletal        | Large animal surgical models (joint/cartilage injury) | Chondrocyte-Seeded Hydrogel Constructs                  | Recreating mechanical loading and assessing repair patterns   | Eliminates large animal surgical protocols          |
| 7.2 Reproductive           | Maternal-fetal animal developmental toxicity studies  | Placental Transport Modelling Platforms                 | Evaluating syncytiotrophoblast transfer kinetics and toxicity | Replaces animal-based reproductive toxicity studies |
| 7.3 Dental                 | Animal oral mucosal and periodontal models            | Human Oral Mucosal Chips & Periodontal Tissue Mapping   | Multi-omic analysis of oral mucosal inflammatory responses    | Replaces legacy biomaterial biocompatibility tests  |
| 7.4 Bone                   | Murine bone density and mineral assays                | Bone Marrow Chips & Bone Density Predictive Algorithms  | High-throughput virtual screening of osteogenic compounds     | Bypasses non-predictive murine bone density assays  |
| 7.5 Cartilage Regeneration | Invasive in vivo cartilage defect models              | Advanced 3D Bioprinting & Mechano-Biological Simulators | Simulating stress-driven drug transfer kinetics               | Streamlines compliance with ASPA 1986               |

3. Alternative Phased Implementation Timelines

| Phase   | Option A: Rapid Institutional Integration Roadmap                                                         | Option B: Phased Risk-Managed Rollout                                                    |
|---------|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Phase 1 | Audit legacy in vivo musculoskeletal and reproductive testing protocols (Months 1–3).                     | Baseline assessment of animal usage across dental and bone density assays (Months 1–6).  |
| Phase 2 | Pilot human oral mucosal chips and 3D hydrogel cartilage platforms (Months 4–9).                          | Introduce placental transport modelling platforms for parallel validation (Months 7–18). |
| Phase 3 | Deploy multi-omic developmental platforms and computational mechano-biological simulators (Months 10–18). | Scale up bio-printed scaffolds and bone marrow chip architectures (Months 19–30).        |
| Phase 4 | Fully transition to Weight of Evidence (WoE) dossiers for PPL applications (Months 19–24).                | Achieve full replacement of high-severity surgical models (Months 31–36).                |

4. Systems Biology Mapping & Technical Capabilities

- Mechano-Biological Simulation:** Translates physical stress and load patterns into predictive computational data to evaluate joint and bone integrity without animal subjects.
- Multi-Omic Integration:** Combines transcriptomic and metabolomic data from microfluidic tissue barriers to generate robust Weight of Evidence (WoE) packages.
- High-Throughput Screening:** Allows early-stage evaluation of biomaterials and osteogenic compounds, mitigating translational failure rates before clinical progression.

# Executive Summary & Compliance Dashboard

## Executive Summary

The assessment of musculoskeletal, reproductive, and dental pathophysiology has historically relied on high-severity *in vivo* testing, which frequently fails to replicate human-specific developmental and mechanical responses. This roadmap mandates a transition to high-fidelity, human-relevant NAMs—specifically organoid and microphysiological systems (MPS)—to replace animal-based testing paradigms. This strategic shift ensures all research is scientifically precise, ethically robust, and fully compliant with the Section 2A statutory duty of the *ASPA 1986*.

## Maturity Matrix

**Phase 1 (Exploratory):** Audit current reliance on animal-based surgical and developmental models.

**Phase 2 (Pilot):** Integrate human-derived joint-on-a-chip, placental barriers, and bio-printed scaffolds.

**Phase 3 (Integration):** Implement quantitative digital platforms for cross-cutting regenerative prediction.

**Phase 4 (Standardisation):** Replace 100% of high-severity animal challenge models with qualified human-relevant NAMs.

**Strategic Note:** Building institutional expertise in high-maturity human-relevant NAMs is essential for bridging the translational gap in these domains. By training staff in the management of complex mechanical interfaces and developmental modelling, the institution fulfills its statutory duty under *ASPA 1986*.

## Integration Context: Roadmap Conclusion

The modules detailed in this roadmap—from the high-fidelity musculoskeletal and reproductive platforms explored here to the broader integrated systems established throughout this series—demonstrate that replacement is not a siloed scientific exercise, but an integrated institutional strategy. By mapping these specialised NAM-based models into a unified regulatory framework, the institution moves decisively toward a standardised, human-centric research paradigm. This systemic integration is the essential prerequisite for fulfilling the *ASPA 1986* statutory duty, ensuring all research is scientifically accurate, ethically aligned, and regulatory compliant.

## Final Compliance Statement

All proposed models satisfy the Section 2A statutory duty of *ASPA 1986*. By adopting these methodologies, the institution positions itself at the forefront of the global transition toward human-centric, cruelty-free medical science.

## Core Specialised Platforms: Scientific & Regulatory Momentum

### 7.1 Musculoskeletal / Joint & Arthritis Models: Inflammation & Mechanics

This section covers human-relevant platforms designed to model the inflammatory microenvironment of joint disease. Landmark momentum in this area includes:

- **Human Joint-on-a-Chip:** Microfluidic systems that replicate human weight-bearing mechanics and cytokine-driven cartilage degradation to study diseases like rheumatoid arthritis.
- **Organotypic Synovial Models:** Advanced platforms used to study rheumatoid arthritis-associated synovial hyperplasia and matrix-modifying cartilage crosstalk.

Artificial Intelligence (AI) and In Silico NAMs Supporting Musculoskeletal Research

To complement advanced in vitro musculoskeletal models, in silico and AI-driven methodologies play a critical role in predicting safety, pharmacology, and therapeutic efficacy:

- **AlphaFold (DeepMind):** An AI system predicting protein structures, RNA, and ligand interactions to support target identification and drug development with far fewer molecules per program.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to predict chemical behavior, real-world biological activity, and safety endpoints with high subpopulation robustness and accuracy.

### 7.2 Reproductive / Placental / Developmental Models: Barrier Integrity & Toxicity

This section covers platforms for modelling placental transport and embryotoxicity. Landmark momentum in this area includes:

- **Placental Barrier-on-a-Chip:** A microfluidic platform that allows for the assessment of maternal-fetal drug transfer kinetics, nutrient tolerance, and conditions like pre-eclampsia without invasive fetal risk.
- **Embryonic Stem Cell Models (Post-Implantation):** Systems that derive tissues from stem cells to study axis elongation, germ layer formation, somite development, and early cardiac-mesodermal differentiation.
- **Blastocyst Models:** Platforms that mimic early embryonic staging (trophectoderm, inner cell mass, and primitive endoderm) to evaluate developmental toxicity (DART).
- **Ovarian / Gonadal Toxicity Models:** In vitro systems used for evaluating endocrine disruption, follicular development, and reproductive toxicity.

Artificial Intelligence (AI) and In Silico NAMs Supporting Reproductive Research

To complement advanced in vitro reproductive and developmental models, in silico and AI-driven methodologies play a critical role in predicting DART endpoints:

- **AlphaFold (DeepMind):** An AI system predicting protein structures and ligand interactions to support the evaluation of reproductive targets and hormone-gland interactions.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to predict developmental and reproductive toxicity, maternal-fetal safety profiles, and chemical behavior with high accuracy.

### 7.3 Dental / Oral Models: Biocompatibility & Inflammation

This section covers models of the oral mucosal barrier. Landmark momentum in this area includes:

- **Human Oral Mucosal Chips:** Advanced microfluidic models that replicate the oral mucosal barrier to evaluate drug absorption and local toxicity.
- **Periodontal Ligament Models:** Specialized systems used for evaluating the biocompatibility of dental implants and analyzing gingival inflammatory responses.

Artificial Intelligence (AI) and In Silico NAMs Supporting Dental & Oral Research

To complement advanced in vitro oral models, in silico and AI-driven methodologies play a critical role in predicting safety and material compatibility:

- **AlphaFold (DeepMind):** An AI system predicting protein structures, RNA, and ligand interactions to support the discovery of biomaterials and targeted therapeutics.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to predict chemical behaviour, biocompatibility, and local toxicity endpoints with high robustness and accuracy.

#### 7.4 Bone / Osteoporosis Models: Remodelling & Mineral Density

This section covers specialised platforms for bone metabolic assessments. Landmark momentum in this area includes:

- **3D Bio-printed Bone Scaffolds:** Precision-engineered structures designed to recreate the extracellular matrix and cellular organization of bone tissue.
- **Bone-Marrow-on-a-Chip Platforms:** Microfluidic systems that recreate the complex human bone marrow niche, vascular support, and microenvironment for studying osteogenic signaling, hematopoiesis, and immune therapies (such as CAR-T).

Artificial Intelligence (AI) and In Silico NAMs Supporting Bone Research

To complement advanced in vitro bone and marrow models, in silico and AI-driven methodologies play a critical role in predicting remodeling mechanics and safety profiles:

- **AlphaFold (DeepMind):** An AI system predicting protein structures, RNA, and ligand interactions to support the development of bone-targeted therapeutics with far fewer molecules per program.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to predict chemical behaviour, mineral density impacts, and metabolic toxicity endpoints with high subpopulation robustness and accuracy.

#### 7.5 Cartilage Regeneration Models: Repair & Therapeutic Efficacy

This section covers platforms for regenerative medicine. Landmark momentum in this area includes:

- **Human Chondrocyte-Seeded Hydrogel Constructs:** Advanced three-dimensional hydrogel models that allow for the study of cartilage repair kinetics, matrix synthesis, and therapeutic efficacy without traditional large-animal surgical models.
- **Osteochondral Joint Units:** Integrated multi-tissue models that replicate the crosstalk between cartilage and subchondral bone to study degenerative joint diseases.

Artificial Intelligence (AI) and In Silico NAMs Supporting Cartilage Research

To complement advanced in vitro cartilage models, in silico and AI-driven methodologies play a critical role in predicting regenerative outcomes and drug screening:

- **AlphaFold (DeepMind):** An AI system predicting protein structures, RNA, and ligand interactions to support the design of matrix-repair molecules and growth factors.
- **Machine Learning & AI Algorithms (e.g., QSAR):** Mathematical models used to predict chemical behavior, biomaterial safety, and therapeutic response kinetics with high subpopulation robustness and accuracy.

## Core Specialised Platforms

These integrated enabling platforms provide the multi-scale predictive power required for regulatory validation in musculoskeletal and reproductive research. By combining real-time biomechanical sensing with advanced computational frameworks, these technologies enable robust "Weight-of-Evidence" (WoE) packages that directly support the replacement of high-severity invasive animal models with human-relevant, predictive data.




**Figure 1: The Human-Relevant Musculoskeletal-Reproductive-Dental Pipeline**

**Description:** A schematic flow diagram illustrating the transition from traditional, low-predictivity animal models (e.g., rodent arthritis models, invasive maternal-fetal studies, and large animal surgical models) to high-fidelity human Microphysiological Systems (MPS). The figure contrasts "Evolutionary Divergence" (e.g., differences in weight-bearing mechanics, placental transport kinetics, and bone remodelling rates) against the "Human-Centric Solution" (i.e., human joint-on-a-chip, placental barrier-on-a-chip, and 3D bio-printed bone scaffolds).

### Table 1: Core Specialised Models Table

| Focus Area          | Primary Animal Model          | NAM Replacement Technology      | ASPA 1986 Status |
|---------------------|-------------------------------|---------------------------------|------------------|
| 7.1 Musculoskeletal | Rodent arthritis models       | Human Joint-on-a-Chip           | High             |
| 7.2 Reproductive    | Maternal-fetal animal studies | Placental Barrier-on-a-Chip     | High             |
| 7.3 Dental          | Animal oral mucosa models     | Human Oral Mucosal Chips        | High             |
| 7.4 Bone            | Invasive bone marrow studies  | Bone-marrow-on-a-Chip           | High             |
| 7.5 Cartilage       | Large animal surgical models  | Bio-printed Hydrogel Constructs | High             |

# Cross-Cutting & Enabling Platforms




**Figure 2: Integration of Predictive Platforms for Regenerative & Developmental Toxicology**

**Description:** A comparative matrix highlighting the reduction of "Translational Failure Rates" by deploying human-specific NAMs in musculoskeletal and reproductive research. It visualises how specialised platforms provide real-time sensing of barrier integrity (e.g., placental transport), mechanical strain (e.g., joint/cartilage loading), and regenerative markers (e.g., bone density and chondrocyte vitality), effectively replacing invasive *in vivo* surgical and developmental toxicity tests.

**Table 2: Genomic, Computational & Framework-Driven Platforms**

| Platform / Model                               | Key Applications                                              | Benefits for Universities & 3Rs                                               |
|------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------|
| <b>In Silico Mechano-Biological Simulators</b> | Predicting cartilage degradation and joint loading stress     | Bypasses large animal surgical models used for joint/cartilage injury studies |
| <b>Placental Transport Modelling</b>           | AI-driven simulation of maternal-fetal drug transfer kinetics | Replaces invasive maternal-fetal animal developmental toxicity studies        |
| <b>Bone Density Predictive Algorithms</b>      | High-throughput virtual screening of osteogenic compounds     | Bypasses animal-based models of osteoporosis and bone mineral density change  |
| <b>Periodontal Tissue Mapping</b>              | Multi-omic analysis of oral mucosal inflammatory responses    | Replaces legacy animal models for testing dental biomaterial biocompatibility |

## Integration Context: Roadmap Conclusion

The modules detailed in this roadmap—from the high-fidelity musculoskeletal and reproductive platforms explored here to the broader integrated systems established throughout this series—demonstrate that replacement is not a siloed scientific exercise, but an integrated institutional strategy. By mapping these specialised NAM-based models into a unified regulatory framework, the institution moves decisively toward a standardised, human-centric research paradigm. This systemic integration is the essential prerequisite for fulfilling the ASPA 1986 statutory duty, ensuring all research is scientifically accurate, ethically aligned, and regulatory compliant.

## Skills • Training, and Capacity Building

Successful adoption of high-maturity Non-Animal Methodologies (NAMs) in musculoskeletal, reproductive, and dental research requires a strategic shift in workforce development. To ensure the long-term success of the platforms outlined in this series, universities should prioritise the following initiatives:

**Integrated Mechano-Biology & Microfluidics:** Training programmes must bridge the gap between human orthopaedic physiology, fluidic circuit engineering, and the computational mechanics required to simulate joint loading and bone remodelling.

**Regulatory Competency:** Staff should receive formal training on "Fit-for-Purpose" qualification and the specific regulatory expectations of the Home Office/ASRU regarding the replacement of high-severity surgical models.

**Technological Literacy:** Skills in 3D bioprinting, human primary stem-cell differentiation, and mechano-responsive organoid maintenance are critical for modern musculoskeletal and reproductive research.

Table 3: Skills • Training and Capacity Building

| Capability Domain | Focus Area                                    | Impact on 3Rs/Replacement                           |
|-------------------|-----------------------------------------------|-----------------------------------------------------|
| Technical         | Advanced 3D bioprinting & hydrogel constructs | Eliminates large animal surgical protocols          |
| Computational     | AI-driven mechano-biological simulations      | Bypasses non-predictive murine bone density assays  |
| Regulatory        | Weight-of-Evidence (WoE) dossier creation     | Streamlines compliance with ASPA 1986               |
| Bioinformatics    | Multi-omic analysis of developmental toxicity | Replaces animal-based reproductive toxicity studies |

## Clinical Translation Studies

### Musculoskeletal & Joint Models

**Disease Modelling:** Human-derived organotypic synovial models and joint-on-a-chip platforms are currently utilised to map inflammatory cascades in rheumatoid arthritis, providing a high-fidelity alternative for screening anti-rheumatic drugs.

**Translational Efficacy:** These platforms facilitate the study of articular cartilage repair by mimicking human weight-bearing dynamics, offering superior predictive capacity compared to canine or equine *in vivo* surgical models.

**Translational Challenges:** Broad clinical application remains focused on improving the long-term mechanical durability of these microphysiological systems to fully replicate chronic degenerative joint conditions.

### Reproductive & Developmental Models

**Safety Assessment:** Placental barrier-on-a-chip technologies are increasingly deployed to study the transport kinetics of therapeutic compounds, providing essential data on maternal-to-fetal transfer that cannot be reliably replicated in rodent gestation models.

**Developmental Toxicity:** iPSC-derived developmental organoids allow researchers to study early-stage embryotoxicity with human-specific cell signalling, significantly reducing the reliance on high-severity maternal-fetal animal studies.

**Regulatory Status:** While still in the developmental phase for full regulatory approval, these systems are gaining traction as high-throughput screening tools for identifying developmental hazards early in the drug discovery pipeline.

Dental & Oral Models

**Biomaterial Integration:** Human oral mucosal chips and periodontal ligament models enable the precise assessment of how new dental implants and restorative biomaterials interact with human gingival tissue.

**Predictive Power:** By capturing the unique inflammatory responses of the human oral cavity, these models provide accurate data on tissue integration, reducing the necessity for animal-based oral biocompatibility testing.

### Summary of Clinical Translational Pathway

Translational researchers are leveraging these systems to identify which preclinical advancements can be successfully developed into human-relevant safety assays. Widespread clinical adoption currently depends on standardised manufacturing scalability, further validation of mechanical stress responses, and continued regulatory guidance to qualify these platforms for formal submission dossiers.

## 1. Vision & Mandate

This roadmap outlines the institutional transition from traditional *in vivo* animal models to high-fidelity, human-relevant Non-Animal Methodologies (NAMs). Driven by the Section 2A statutory duty of the *Animals (Scientific Procedures) Act 1986*, this strategy prioritises the adoption of human-centric platforms to enhance the scientific validity, reproducibility, and ethical alignment of our research output.

## 2. Landmark Regulatory & Scientific Momentum

**Musculoskeletal / Joint & Arthritis Models (7.1):** Utilising human joint-on-a-chip and organotypic synovial models to replicate the inflammatory microenvironment of rheumatoid and osteoarthritis, replacing legacy rodent models.

**Reproductive / Placental / Developmental Models (7.2):** Implementing human placental barrier-on-a-chip and developmental toxicity organoids to accurately model barrier transport and embryotoxicity, superseding invasive maternal-fetal animal studies.

**Dental / Oral Models (7.3):** Adopting human oral mucosal chips and periodontal ligament models to evaluate biomaterial integration and gingival inflammatory responses.

**Bone / Osteoporosis Models (7.4):** Deploying 3D bio-printed bone scaffolds and microphysiological bone-marrow-on-a-chip platforms to study osteogenic signalling and drug effects in human-relevant bone metabolism.

**Cartilage Regeneration Models (7.5):** Integrating human chondrocyte-seeded hydrogel constructs and mechano-responsive cartilage chips to study therapeutic interventions in cartilage repair, eliminating canine and equine *in vivo* surgical models.

## 3. Strategic De-Risking

**Financial & Temporal Efficiency:** Early-stage identification of off-target toxicities via NAMs prevents the catastrophic costs associated with late-stage clinical trial failures.

**Precision Modelling:** Moving away from rodent models mitigates the risk of "false positives" driven by species-specific metabolic differences that do not occur in humans.

**Data Integrity:** Transitioning to human-derived data strengthens "Weight-of-Evidence" submissions, directly increasing the probability of project license (PPL) approval by the Home Office/ASRU.

## 4. Compliance & Institutional Commitment

**Integration Context:** Mapping these specialised models into a unified regulatory framework is the essential prerequisite for fulfilling our *ASPA 1986* statutory duty, ensuring all research is scientifically accurate and ethically aligned.

**Final Compliance Statement:** All proposed models satisfy the Section 2A statutory duty of *ASPA 1986*. By adopting these methodologies, the institution positions itself at the forefront of the global transition toward human-centric, cruelty-free medical science.